Diabetes, Obesity & Metabolism

SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population-Based Cross-Sectional Study of Uptake of NICE Guidance

By Patrick Y Muller, Jonathan Wray, Muksitur Rahman, Lesley Owen

Study in peoplePopulations

The paper

Patrick Y Muller, Jonathan Wray, Muksitur Rahman, Lesley Owen

National Institute for Health and Care Excellence

Diabetes, Obesity & Metabolism, 4 Aug 2026

doi.org/10.1111/dom.71010 PubMed 42552240

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes